Carfilnat-carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
CARFILNAT is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Source Content From US FDA
Brand Name "Carfilnat (carfilzomib) for Injection" medication can be imported and made available on "Named Patient Program (NPP)" treatment in Philippines, Vietnam, Ireland and India. Please contact at +91 9910645395 (Mr. Rakesh) or make an enquiry at info@cancermedicinesnetwork to find the cost price to buy "Carfilnat (carfilzomib) for Injection" online and have it delivered where you live. We take guarantee of quality and delivery as per the buyer’s requirements.
Patient, Physcian, distributor/supplier can buy and import Brand Name "Carfilnat (carfilzomib) for Injection" from Verve Biosciences, if the drug has not been approved or is not available in your country. Make an enquiry and we will help you calculate the total price to buy "Carfilnat (carfilzomib) for Injection" online and have it delivered where you live. From your side, we’ll simply need a prescription from your treating doctor. In some countries we might also need an import license. Our Patient Support team will guide you throughout the process.
Verve Biosciences facilitates import of anti-cancer medicines Carfilnat (carfilzomib) for Injection, Make an enquiry to find the total cost of Carfilnat (carfilzomib) for Injection in UAE, Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.